Tagip 25mg Tablet contains Sitagliptin, an oral antidiabetic medicine used for the treatment of type 2 diabetes mellitus. It belongs to the DPP-4 inhibitor class, which works by increasing insulin release and decreasing glucose production in the body. It helps control blood sugar levels, especially after meals, and lowers the risk of diabetes-related complications when…
Tagipmet 50/500 mg Tablet combines Sitagliptin (50 mg) and Metformin (500 mg) to help manage blood glucose levels in type 2 diabetes, improving insulin response and lowering excess sugar production.
100/1000 mg Tablet is an extended-release (XR) formulation containing Sitagliptin (100 mg) and Metformin (1000 mg), used for better long-term control of blood sugar in type 2 diabetes with once-daily dosing.
This pack of Tagipmet XR 50/1000 mg (20s) also contains Sitagliptin and Metformin (extended-release), used to manage type 2 diabetes by controlling blood glucose levels throughout the day.
This pack of Tagipmet XR 50/1000 mg (20s) also contains Sitagliptin and Metformin (extended-release), used to manage type 2 diabetes by controlling blood glucose levels throughout the day.
Tagipmet XR 50/500 mg Tablet contains Sitagliptin (50 mg) and Metformin (500 mg) in an extended-release form. It is used to manage type 2 diabetes by controlling blood sugar levels, improving insulin release, and reducing glucose production in the liver.
Used for self-monitoring of blood glucose levels at home.Provides accurate and quick results with minimal blood sample.Essential for people managing diabetes on a daily basis.
Xenglu Met XR combines [active ingredients: Vildagliptin 12.5mg + Metformin HCl 1000mg], helping to manage blood sugar levels in adults with type 2 diabetes. It works by increasing insulin release and improving the body’s response to insulin, while reducing glucose production in the liver. Key Uses: Helps control high blood sugar in type 2 diabetes…
In order to provide you a personalized shopping experience, our site uses cookies. By continuing to use this site, you are agreeing to our cookie policy.